Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
Becton Dickinson said today is once again extending its exchange offering for up to $1.1 billion in outstanding C. R. Bard notes from July 3 to August 1.
The company is offering exchanges for approximately $500 million for 4.4% Bard note due 2021, $500 million for 3% notes due 2026 and $149.8 million in 6.7% notes due 2026. Read more
Abbott said today that its FreeStyle Libre glucose monitoring system won Health Canada approval for adults with diabetes.
The company’s disposable glucose monitoring device is worn on the back of the upper arm and senses glucose using a small filament that is placed under the skin. Every scan includes a real-time glucose reading, as well as an 8-hour snapshot of blood sugar data. Read more
Second Sight Medical said today its Argus II retinal prosthesis system won expanded reimbursement coverage from the Centers for Medicare and Medicaid Services in 11 additional states and the District of Columbia.
With the expansion, the Sylmar, Calif.-based company said it’s Argus II device is now reimbursable in 7 of the 12 Medicare Administrative Contractor jurisdictions, covering the device in a total of 28 states, 2 territories and D.C. Read more
The future of medical technology could involve artificial intelligence, virtual reality and even direct connections to the human brain. A panel at DeviceTalks, lead by Worrell Design’s director of advanced development, Derek Mathers, discussed how technological developments like Amazon’s Alexa and the accumulation of big data could shape future trends in medtech. Read more
Medtronic is closing in on a resolution to the long-running legal battles over its Infuse bone-growth protein designed for back surgeries, according to an SEC filing posted last week.
The Fridley, Minn.-based company said that it is approaching agreements to settle approximately 6,000 cases against it which asserted personal injury claims due to the bone graft product in an SEC filing. Read more